LYN and systemic lupus erythematosus: To further support the correlation between Lyn expression and immune‐related disorders, the onset of immune‐mediated‐thrombotic thrombocytopenic purpura and lupus‐like symptoms were observed in patients treated with dasatinib, another dual‐acting Bcr‐Abl/Src kinase inhibitor [12, 13].